COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Overview
NASDAQ:COLL - US19459J1043 - Common Stock
COLL Key Statistics, Chart & Performance
The current stock price of COLL is 38.35 USD. In the past month the price increased by 28.43%. In the past year, price decreased by -0.29%.
COLL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.32 | 692.77B | ||
| JNJ | JOHNSON & JOHNSON | 17.54 | 422.54B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.35 | 249.32B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.02 | 248.01B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.29 | 244.83B | ||
| MRK | MERCK & CO. INC. | 10.81 | 207.84B | ||
| PFE | PFIZER INC | 7.26 | 139.86B | ||
| SNY | SANOFI-ADR | 11.27 | 121.80B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.97 | 95.42B | ||
| GSK | GSK PLC-SPON ADR | 8.71 | 79.50B | ||
| ZTS | ZOETIS INC | 24.89 | 68.60B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.9 | 47.28B |
Related stock screener links
About COLL
Company Profile
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 357 full-time employees. The company went IPO on 2015-05-07. The firm has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
Company Info
COLLEGIUM PHARMACEUTICAL INC
100 Technology Center Dr
Stoughton MASSACHUSETTS 02072 US
CEO: Joseph Ciaffoni
Employees: 357
Phone: 17817133699
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What is the stock price of COLLEGIUM PHARMACEUTICAL INC today?
The current stock price of COLL is 38.35 USD. The price decreased by -1.13% in the last trading session.
What is the ticker symbol for COLLEGIUM PHARMACEUTICAL INC stock?
The exchange symbol of COLLEGIUM PHARMACEUTICAL INC is COLL and it is listed on the Nasdaq exchange.
On which exchange is COLL stock listed?
COLL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for COLLEGIUM PHARMACEUTICAL INC stock?
11 analysts have analysed COLL and the average price target is 45.49 USD. This implies a price increase of 18.62% is expected in the next year compared to the current price of 38.35. Check the COLLEGIUM PHARMACEUTICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is COLLEGIUM PHARMACEUTICAL INC worth?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a market capitalization of 1.21B USD. This makes COLL a Small Cap stock.
How many employees does COLLEGIUM PHARMACEUTICAL INC have?
COLLEGIUM PHARMACEUTICAL INC (COLL) currently has 357 employees.
What are the support and resistance levels for COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a support level at 38.34. Check the full technical report for a detailed analysis of COLL support and resistance levels.
Is COLLEGIUM PHARMACEUTICAL INC (COLL) expected to grow?
The Revenue of COLLEGIUM PHARMACEUTICAL INC (COLL) is expected to grow by 20.25% in the next year. Check the estimates tab for more information on the COLL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of COLL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of COLL, evaluating the profitability, health, valuation and growth aspects
- COLLEGIUM PHARMACEUTICAL INC (COLL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- COLLEGIUM PHARMACEUTICAL INC (COLL) Sales and EPS estimates to see what analysts future expectations are.
- COLLEGIUM PHARMACEUTICAL INC (COLL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- COLLEGIUM PHARMACEUTICAL INC (COLL) Insider and Institutional Ownership to learn about the owners and their transactions.
- COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Chart to make your own analysis
- COLLEGIUM PHARMACEUTICAL INC (COLL) Latest news and press-releases to stay up to date.
Does COLLEGIUM PHARMACEUTICAL INC (COLL) stock pay dividends?
COLL does not pay a dividend.
When does COLLEGIUM PHARMACEUTICAL INC (COLL) report earnings?
COLLEGIUM PHARMACEUTICAL INC (COLL) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of COLLEGIUM PHARMACEUTICAL INC (COLL)?
The PE ratio for COLLEGIUM PHARMACEUTICAL INC (COLL) is 5.85. This is based on the reported non-GAAP earnings per share of 6.55 and the current share price of 38.35 USD. Check the full fundamental report for a full analysis of the valuation metrics for COLL.
What is the Short Interest ratio of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
The outstanding short interest for COLLEGIUM PHARMACEUTICAL INC (COLL) is 13.63% of its float. Check the ownership tab for more information on the COLL short interest.
COLL Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to COLL. When comparing the yearly performance of all stocks, COLL is one of the better performing stocks in the market, outperforming 75.64% of all stocks.
COLL Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to COLL. COLL has an excellent profitability rating, but there are some minor concerns on its financial health.
COLL Financial Highlights
Over the last trailing twelve months COLL reported a non-GAAP Earnings per Share(EPS) of 6.55. The EPS increased by 48.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.13% | ||
| ROA | 2.28% | ||
| ROE | 15.62% | ||
| Debt/Equity | 3.27 |
COLL Forecast & Estimates
11 analysts have analysed COLL and the average price target is 45.49 USD. This implies a price increase of 18.62% is expected in the next year compared to the current price of 38.35.
For the next year, analysts expect an EPS growth of 30.62% and a revenue growth 20.25% for COLL